A recent case series study completed at The Welsh Wound Innovation Centre was presented at The Wounds UK Annual Conference this November.
The study details the use of CovaWound™ Alginate for nine patients, all of whom had complex co-morbidites and wounds that were complex and ‘hard to heel’. Upon examination, all wounds were moderate to highly exuding and of mixed, venous or diabetic foot aetiology without clinical features of infection.
Each patient was reviewed over a 4-week period and the wound status was evaluated weekly utilising both objective and subjective assessment methods, which included wound tracing and wound photographs.
Findings showed that CovaWound™ Alginate was ‘very good’ at controlling exudate, as well as being easy to apply and remove. The dressing was found to demonstrate high absorbency with no peri-wound maceration of the surrounding skin. Clinicians reported that the dressing was highly conformable and retained integrity on removal from the wound bed. The study also found that there was no additional pain during dressing changes and concluded that CovaWound™ Alginate is an effective dressing when used under compression therapy.
Please follow the link below to view the study findings.
*References cited in ‘Alginate FAQs’ found within the resources section of our website.
**Drug Tariff published pricing, December 2019.
Covalon Technologies (Europe) Ltd, No 1 Mill, The Wharf, Shardlow, Derbyshire, DE72 2GH
T: +44 (0) 1332 322469